Eledon Pharmaceuticals Inc (ELDN)

$3.58 0.00 (N/A)
Market Cap 293.31M
Revenue (ttm) 0.00
Net Income (ttm) -45.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 873,300
Avg Vol 1,576,064
Day's Range N/A - N/A
Shares Out 77.19M
Stochastic %K 10%
Beta 0.94
Analysts Strong Sell
Price Target $8.33

Company Profile

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for th...

Industry: Biotechnology
Sector: Healthcare
Phone: 949 238 8090
Website: eledon.com
Address:
19800 MacArthur Boulevard, Suite 250, Irvine, United States
Feenz
Feenz May. 19 at 9:11 PM
$ELDN picked up some more at 3.50. Cost basis still under $3 🤘. Not worried about a capital raise. Breakthroughs cost money and I believe they are on the verge of something great.
1 · Reply
Penny_stock_Raid_Boss
Penny_stock_Raid_Boss May. 19 at 6:00 PM
$ELDN the bounce...
1 · Reply
Soupdog420
Soupdog420 May. 19 at 12:54 PM
$SLS this is my big play ...but $ELDN is looking good i good 800 share but think it might be to early to look for long holds.and i shukd start flipping it more .... Any thoughts from yall. ... only asking old school sls folks . I've played this one for years and know late stage 3 last year was the time to go all inn and let maturing of tax breaks
1 · Reply
sethsethsethseth
sethsethsethseth May. 18 at 2:53 PM
$ELDN buy more
0 · Reply
Tryingtobebetter
Tryingtobebetter May. 18 at 2:35 PM
$ELDN this is what I was saying. Waiting for the dust to settle. Starting a small add now.
1 · Reply
Penny_stock_Raid_Boss
Penny_stock_Raid_Boss May. 18 at 2:13 PM
$ELDN 3.5 i called, it give it me.
1 · Reply
Ontherag
Ontherag May. 18 at 2:07 PM
$ELDN ouch, 40M spent in Q1!
0 · Reply
mhaven2020
mhaven2020 May. 18 at 1:48 PM
$ELDN $APPS $RXT I will probably in start entering into $OBIO and $PEW for a couple of days. Entry (PEW) @ 2.75 to 2.87 and (OBIO) 3.50 to 3.77. Expected hold time of between 14 and 20 days . Expected return 20% +. I am on day 19 of an expected hold time of 25. My current entry is averaged down to 3.75 and target exit of between 4.15 and 4.37. This would yield between a 10% and 16% profit. Good Luck and Happy Hunting!
0 · Reply
Channelchek
Channelchek May. 18 at 1:44 PM
Noble Capital Markets Research Report: Eledon Pharmaceuticals ($ELDN) – Eledon Confirms Clinical Milestones With 1Q26 Report 1Q26 Report Included Milestones For FY2026. Eledon reported a Loss From Operations of $21.2 million, before interest income and a non-cash charge of $19.0 million from Changes in the Fair Value of Warrant Liabilities. This brought the 1Q26 Net Loss to $39.0 million or $(0.33) per share. Read full report here: https://www.channelchek.com/news-channel/eledon-pharmaceuticals-eldn-eledon-confirms-clinical-milestones-with-1q26-report
0 · Reply
cwork
cwork May. 18 at 12:25 AM
$ELDN https://youtube.com/shorts/nDz96DMWjzo?si=gsKROraxSnbUsn36
0 · Reply
Latest News on ELDN
Eledon Pharmaceuticals reports Q1 EPS (33c), consensus (23c)

2026-05-13T21:28:34.000Z - 6 days ago

Eledon Pharmaceuticals reports Q1 EPS (33c), consensus (23c)

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 13, 2026, 4:05 PM EDT - 6 days ago

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

Eledon Pharmaceuticals Earnings release: Q1 2026

May 13, 2026, 4:00 PM EDT - 6 days ago

Eledon Pharmaceuticals Earnings release: Q1 2026

Eledon Pharmaceuticals Quarterly report: Q1 2026

May 13, 2026, 4:00 PM EDT - 6 days ago

Eledon Pharmaceuticals Quarterly report: Q1 2026

Eledon Pharmaceuticals files $500M mixed securities shelf

2026-05-01T20:15:19.000Z - 18 days ago

Eledon Pharmaceuticals files $500M mixed securities shelf

Eledon Pharmaceuticals Registration statement: Registration filing

May 1, 2026, 8:00 AM EDT - 18 days ago

Eledon Pharmaceuticals Registration statement: Registration filing

Eledon Pharmaceuticals Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 19 days ago

Eledon Pharmaceuticals Proxy statement: Proxy filing

Eledon Pharmaceuticals Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 19 days ago

Eledon Pharmaceuticals Proxy statement: Proxy filing

Eledon Pharmaceuticals Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 4 weeks ago

Eledon Pharmaceuticals Proxy statement: Proxy filing

NewcelX announces release of updated presentation on Type 1 Diabetes program

2026-04-20T11:43:42.000Z - 4 weeks ago

NewcelX announces release of updated presentation on Type 1 Diabetes program

NCEL

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results

Mar 19, 2026, 5:10 PM EDT - 2 months ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results

Eledon Pharmaceuticals Annual report: Q4 2025

Mar 19, 2026, 4:00 PM EDT - 2 months ago

Eledon Pharmaceuticals Annual report: Q4 2025

Eledon Pharmaceuticals Earnings release: Q4 2025

Mar 19, 2026, 4:00 PM EDT - 2 months ago

Eledon Pharmaceuticals Earnings release: Q4 2025

Eledon Pharmaceuticals options imply 11.7% move in share price post-earnings

2026-03-19T19:20:17.000Z - 2 months ago

Eledon Pharmaceuticals options imply 11.7% move in share price post-earnings

Eledon announces updated data from islet transplant trial of tegoprubart

2026-03-16T11:30:46.000Z - 2 months ago

Eledon announces updated data from islet transplant trial of tegoprubart

Eledon Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 1:40 PM EDT - 2 months ago

Eledon Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Eledon Pharmaceuticals announces U.S. FDA granted ODD to tegoprubart

2026-03-10T11:16:45.000Z - 2 months ago

Eledon Pharmaceuticals announces U.S. FDA granted ODD to tegoprubart

Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation

Mar 10, 2026, 7:00 AM EDT - 2 months ago

Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation

NewcelX announces research agreement with Eledon Pharmaceuticals

2026-03-09T11:12:39.000Z - 2 months ago

NewcelX announces research agreement with Eledon Pharmaceuticals

NCEL

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

Mar 9, 2026, 7:00 AM EDT - 2 months ago

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

NCEL

Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference

Mar 4, 2026, 4:05 PM EST - 2 months ago

Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference

Eledon Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 12, 2026, 10:00 AM EST - 3 months ago

Eledon Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 4:10 PM EST - 3 months ago

Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Eledon Pharmaceuticals presents long-term Phase 1b data for tegoprubart

2026-01-23T12:05:49.000Z - 4 months ago

Eledon Pharmaceuticals presents long-term Phase 1b data for tegoprubart

Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium

Jan 23, 2026, 7:00 AM EST - 4 months ago

Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook

Jan 8, 2026, 4:05 PM EST - 4 months ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook

Eledon Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 4, 2025, 8:50 AM EST - 5 months ago

Eledon Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference

Dec 1, 2025, 7:00 AM EST - 6 months ago

Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference

Eledon Pharmaceuticals reports preliminary tegoprubart trial results

2025-11-18T21:15:53.000Z - 6 months ago

Eledon Pharmaceuticals reports preliminary tegoprubart trial results

Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Nov 18, 2025, 4:05 PM EST - 6 months ago

Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Eledon Pharmaceuticals price target lowered to $8 from $9 at Guggenheim

2025-11-18T11:35:08.000Z - 6 months ago

Eledon Pharmaceuticals price target lowered to $8 from $9 at Guggenheim

Eledon Pharmaceuticals reports Q3 EPS (21c), consensus (25c)

2025-11-14T22:05:10.000Z - 6 months ago

Eledon Pharmaceuticals reports Q3 EPS (21c), consensus (25c)

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Nov 14, 2025, 5:00 PM EST - 6 months ago

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Eledon Pharmaceuticals Earnings release: Q3 2025

Nov 14, 2025, 4:00 PM EST - 6 months ago

Eledon Pharmaceuticals Earnings release: Q3 2025

Eledon Pharmaceuticals Quarterly report: Q3 2025

Nov 14, 2025, 4:00 PM EST - 6 months ago

Eledon Pharmaceuticals Quarterly report: Q3 2025

Eledon Pharmaceuticals options imply 14.1% move in share price post-earnings

2025-11-14T18:50:40.000Z - 6 months ago

Eledon Pharmaceuticals options imply 14.1% move in share price post-earnings

Eledon Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 12, 2025, 10:30 AM EST - 6 months ago

Eledon Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Eledon prices 15.15M shares at $1.65 in underwritten public offering

2025-11-12T13:00:22.000Z - 6 months ago

Eledon prices 15.15M shares at $1.65 in underwritten public offering

Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Nov 12, 2025, 7:56 AM EST - 6 months ago

Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Eledon Pharmaceuticals announces common stock, warrant offering, no amount given

2025-11-11T22:30:20.000Z - 6 months ago

Eledon Pharmaceuticals announces common stock, warrant offering, no amount given

Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Nov 11, 2025, 5:26 PM EST - 6 months ago

Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Eledon Pharmaceuticals options imply 8.0% move in share price post-earnings

2025-11-11T19:20:16.000Z - 6 months ago

Eledon Pharmaceuticals options imply 8.0% move in share price post-earnings

Why Is Eledon Pharmaceuticals Stock (ELDN) Down 50% Today?

2025-11-07T13:50:49.000Z - 6 months ago

Why Is Eledon Pharmaceuticals Stock (ELDN) Down 50% Today?

Eledon Pharmaceuticals Transcript: Study Result

Nov 7, 2025, 8:00 AM EST - 6 months ago

Eledon Pharmaceuticals Transcript: Study Result

Eledon Pharmaceuticals Press release: Study Result

Nov 7, 2025, 8:00 AM EST - 6 months ago

Eledon Pharmaceuticals Press release: Study Result

Eledon Pharmaceuticals Slides: Study Result

Nov 7, 2025, 8:00 AM EST - 6 months ago

Eledon Pharmaceuticals Slides: Study Result

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting

Nov 6, 2025, 6:30 PM EST - 6 months ago

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting

Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference

Nov 5, 2025, 7:00 AM EST - 6 months ago

Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference

Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting

Oct 17, 2025, 7:00 AM EDT - 7 months ago

Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting

Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association

Sep 24, 2025, 4:05 PM EDT - 8 months ago

Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association

Eledon Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Sep 5, 2025, 9:10 AM EDT - 9 months ago

Eledon Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025

Aug 29, 2025, 7:00 AM EDT - 9 months ago

Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025

Eledon Pharmaceuticals reports Q2 EPS (13c), consensus (23c)

2025-08-14T20:25:14.000Z - 9 months ago

Eledon Pharmaceuticals reports Q2 EPS (13c), consensus (23c)

Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results

Aug 14, 2025, 4:20 PM EDT - 9 months ago

Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results

Eledon Pharmaceuticals Quarterly report: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 9 months ago

Eledon Pharmaceuticals Quarterly report: Q2 2025

Eledon Pharmaceuticals Earnings release: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 9 months ago

Eledon Pharmaceuticals Earnings release: Q2 2025

Eledon Pharmaceuticals announces updated data from tegoprubart trial

2025-08-07T09:55:52.000Z - 10 months ago

Eledon Pharmaceuticals announces updated data from tegoprubart trial

Eledon Pharmaceuticals Transcript: Study Update

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Eledon Pharmaceuticals Transcript: Study Update

Eledon Pharmaceuticals Press release: Study Update

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Eledon Pharmaceuticals Press release: Study Update

Eledon Pharmaceuticals Slides: Study Update

Aug 6, 2025, 4:30 PM EDT - 10 months ago

Eledon Pharmaceuticals Slides: Study Update

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Aug 6, 2025, 4:01 PM EDT - 10 months ago

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

Jul 30, 2025, 4:05 PM EDT - 10 months ago

Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

Craig-Hallum bullish on Eledon Pharmaceuticals, initiates with a Buy

2025-07-25T12:46:33.000Z - 10 months ago

Craig-Hallum bullish on Eledon Pharmaceuticals, initiates with a Buy

Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025

Jul 17, 2025, 4:01 PM EDT - 10 months ago

Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025

Eledon Pharmaceuticals Transcript: R&D Day 2025

Jul 9, 2025, 8:30 AM EDT - 11 months ago

Eledon Pharmaceuticals Transcript: R&D Day 2025

Eledon Pharmaceuticals Slides: FY 2025

Jul 9, 2025, 8:30 AM EDT - 11 months ago

Eledon Pharmaceuticals Slides: FY 2025

Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City

Jun 25, 2025, 4:01 PM EDT - 11 months ago

Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

May 14, 2025, 4:01 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

Eledon Pharmaceuticals Quarterly report: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Quarterly report: Q1 2025

Eledon Pharmaceuticals Earnings release: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Earnings release: Q1 2025

Eledon Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Proxy statement: Proxy Filing

Eledon Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Proxy statement: Proxy Filing

Eledon Pharmaceuticals Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Proxy statement: Proxy Filing

Eledon Pharmaceuticals Slides: Corporate Presentation

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Slides: Corporate Presentation

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Mar 20, 2025, 4:01 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Eledon Pharmaceuticals Annual report: Q4 2024

Mar 20, 2025, 4:00 PM EDT - 1 year ago

Eledon Pharmaceuticals Annual report: Q4 2024

Eledon Pharmaceuticals Earnings release: Q4 2024

Mar 20, 2025, 4:00 PM EDT - 1 year ago

Eledon Pharmaceuticals Earnings release: Q4 2024

Eledon Pharmaceuticals Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 2:20 PM EDT - 1 year ago

Eledon Pharmaceuticals Transcript: Leerink’s Global Healthcare Conference 2025

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

Mar 4, 2025, 4:05 PM EST - 1 year ago

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Feb 7, 2025, 10:00 AM EST - 1 year ago

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Eledon Pharmaceuticals Transcript: Guggenheim SMID Cap Biotech Conference

Feb 5, 2025, 1:00 PM EST - 1 year ago

Eledon Pharmaceuticals Transcript: Guggenheim SMID Cap Biotech Conference

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

Jan 29, 2025, 4:05 PM EST - 1 year ago

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Jan 13, 2025, 7:00 AM EST - 1 year ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Eledon Pharmaceuticals Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 13, 2024, 1:30 PM EST - 1 year ago

Eledon Pharmaceuticals Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Nov 12, 2024, 4:01 PM EST - 1 year ago

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Eledon Pharmaceuticals Quarterly report: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Eledon Pharmaceuticals Quarterly report: Q3 2024

Eledon Pharmaceuticals Earnings release: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Eledon Pharmaceuticals Earnings release: Q3 2024

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Oct 29, 2024, 7:46 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Oct 29, 2024, 7:45 AM EDT - 1 year ago

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Eledon Pharmaceuticals Registration statement: Registration Filing

Sep 20, 2024, 8:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Registration statement: Registration Filing

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Sep 11, 2024, 4:05 PM EDT - 1 year ago

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Sep 4, 2024, 7:00 AM EDT - 1 year ago

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

Aug 14, 2024, 5:21 PM EDT - 1 year ago

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

Eledon Pharmaceuticals Quarterly report: Q2 2024

Aug 14, 2024, 3:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Quarterly report: Q2 2024

Eledon Pharmaceuticals Earnings release: Q2 2024

Aug 14, 2024, 3:00 AM EDT - 1 year ago

Eledon Pharmaceuticals Earnings release: Q2 2024

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

Jul 2, 2024, 4:05 PM EDT - 2 years ago

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

Eledon Pharmaceuticals Proxy statement: Proxy Filing

May 30, 2024, 8:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Proxy statement: Proxy Filing

Eledon Pharmaceuticals Proxy statement: Proxy Filing

May 30, 2024, 8:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Proxy statement: Proxy Filing

Eledon Pharmaceuticals Registration statement: Registration Filing

May 24, 2024, 8:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Registration statement: Registration Filing

Eledon Pharmaceuticals Quarterly report: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Eledon Pharmaceuticals Quarterly report: Q1 2024

Eledon Pharmaceuticals Earnings release: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Eledon Pharmaceuticals Earnings release: Q1 2024

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

May 9, 2024, 7:30 AM EDT - 2 years ago

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress

May 9, 2024, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

May 7, 2024, 7:05 AM EDT - 2 years ago

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Mar 28, 2024, 4:01 PM EDT - 2 years ago

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Eledon Pharmaceuticals Annual report: Q4 2023

Mar 28, 2024, 4:00 PM EDT - 2 years ago

Eledon Pharmaceuticals Annual report: Q4 2023

Eledon Pharmaceuticals Earnings release: Q4 2023

Mar 28, 2024, 4:00 PM EDT - 2 years ago

Eledon Pharmaceuticals Earnings release: Q4 2023

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Mar 25, 2024, 4:56 PM EDT - 2 years ago

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Mar 21, 2024, 10:31 AM EDT - 2 years ago

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 13, 2024, 7:01 PM EST - 2 years ago

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

Jan 4, 2024, 4:40 PM EST - 2 years ago

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference

Nov 29, 2023, 4:05 PM EST - 2 years ago

Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference

Eledon Pharmaceuticals Transcript: 14th Annual Jefferies London Healthcare Conference 2023

Nov 16, 2023, 3:00 AM EST - 2 years ago

Eledon Pharmaceuticals Transcript: 14th Annual Jefferies London Healthcare Conference 2023

Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

Nov 9, 2023, 4:01 PM EST - 2 years ago

Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

Eledon Pharmaceuticals Quarterly report: Q3 2023

Nov 9, 2023, 4:00 PM EST - 2 years ago

Eledon Pharmaceuticals Quarterly report: Q3 2023

Eledon Pharmaceuticals Earnings release: Q3 2023

Nov 9, 2023, 4:00 PM EST - 2 years ago

Eledon Pharmaceuticals Earnings release: Q3 2023

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

Nov 8, 2023, 4:05 PM EST - 2 years ago

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

Eledon Pharmaceuticals Transcript: Study Update

Nov 2, 2023, 5:00 PM EDT - 2 years ago

Eledon Pharmaceuticals Transcript: Study Update

Eledon Pharmaceuticals Press release: Study Update

Nov 2, 2023, 5:00 PM EDT - 2 years ago

Eledon Pharmaceuticals Press release: Study Update

Eledon Pharmaceuticals Slides: Study Update

Nov 2, 2023, 5:00 PM EDT - 2 years ago

Eledon Pharmaceuticals Slides: Study Update

Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Nov 2, 2023, 9:05 AM EDT - 2 years ago

Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals Slides: Investor Presentation

Nov 1, 2023, 8:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Slides: Investor Presentation

Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer

Feenz
Feenz May. 19 at 9:11 PM
$ELDN picked up some more at 3.50. Cost basis still under $3 🤘. Not worried about a capital raise. Breakthroughs cost money and I believe they are on the verge of something great.
1 · Reply
Penny_stock_Raid_Boss
Penny_stock_Raid_Boss May. 19 at 6:00 PM
$ELDN the bounce...
1 · Reply
Soupdog420
Soupdog420 May. 19 at 12:54 PM
$SLS this is my big play ...but $ELDN is looking good i good 800 share but think it might be to early to look for long holds.and i shukd start flipping it more .... Any thoughts from yall. ... only asking old school sls folks . I've played this one for years and know late stage 3 last year was the time to go all inn and let maturing of tax breaks
1 · Reply
sethsethsethseth
sethsethsethseth May. 18 at 2:53 PM
$ELDN buy more
0 · Reply
Tryingtobebetter
Tryingtobebetter May. 18 at 2:35 PM
$ELDN this is what I was saying. Waiting for the dust to settle. Starting a small add now.
1 · Reply
Penny_stock_Raid_Boss
Penny_stock_Raid_Boss May. 18 at 2:13 PM
$ELDN 3.5 i called, it give it me.
1 · Reply
Ontherag
Ontherag May. 18 at 2:07 PM
$ELDN ouch, 40M spent in Q1!
0 · Reply
mhaven2020
mhaven2020 May. 18 at 1:48 PM
$ELDN $APPS $RXT I will probably in start entering into $OBIO and $PEW for a couple of days. Entry (PEW) @ 2.75 to 2.87 and (OBIO) 3.50 to 3.77. Expected hold time of between 14 and 20 days . Expected return 20% +. I am on day 19 of an expected hold time of 25. My current entry is averaged down to 3.75 and target exit of between 4.15 and 4.37. This would yield between a 10% and 16% profit. Good Luck and Happy Hunting!
0 · Reply
Channelchek
Channelchek May. 18 at 1:44 PM
Noble Capital Markets Research Report: Eledon Pharmaceuticals ($ELDN) – Eledon Confirms Clinical Milestones With 1Q26 Report 1Q26 Report Included Milestones For FY2026. Eledon reported a Loss From Operations of $21.2 million, before interest income and a non-cash charge of $19.0 million from Changes in the Fair Value of Warrant Liabilities. This brought the 1Q26 Net Loss to $39.0 million or $(0.33) per share. Read full report here: https://www.channelchek.com/news-channel/eledon-pharmaceuticals-eldn-eledon-confirms-clinical-milestones-with-1q26-report
0 · Reply
cwork
cwork May. 18 at 12:25 AM
$ELDN https://youtube.com/shorts/nDz96DMWjzo?si=gsKROraxSnbUsn36
0 · Reply
mhaven2020
mhaven2020 May. 17 at 1:35 AM
$ELDN $APPS $RXT Here is my semi-finals list if anyone wants to play along.
0 · Reply
Penny_stock_Raid_Boss
Penny_stock_Raid_Boss May. 15 at 7:37 PM
$ELDN aaaaand one of the two Fudbots low IQ finally gave up. One left.
1 · Reply
red1
red1 May. 15 at 1:29 PM
$ELDN we may go up a lot today let’s see
1 · Reply
Veraton
Veraton May. 14 at 11:40 PM
$ELDN we can have several scenarios here:::: 1. Buyout 2. Big commercial collaboration 3. There's big pharma that need tego for consolidating their pipelines and existing drugs already FDA approved... It makes it difficult who will bite, cause they are in different medicine sectors... We already know this... 4. Graph numbers are improving by the month 5. 10 out of 10 diabetes patients cured 6. Enrolling xxx more in UM 7. university of Chicago with dr. Piotr advancing in results by the hour... 8... Etc etc
3 · Reply
BriOnH
BriOnH May. 14 at 11:17 PM
$ELDN C&H forming on the daily. Entry is above 4.15, stop is at 3.63, limit is tough to measure on here, it either breaks out or it doesn't. 66% chance of a breakout.
1 · Reply
JCLuckman
JCLuckman May. 14 at 10:42 PM
$ELDN with the raise last November I thought the stock was a Buy. Now that we're at $4 again, I'm not sure what to think about where this going. Do they partner? Do they get BO? Do they raise again and repeat? I love the promise of their product, but wondering what others think about just where the company is in that cycle.
1 · Reply
mhaven2020
mhaven2020 May. 14 at 10:30 PM
$ELDN $RXT Here are the 3rd layer of results so everyone can see. The 1st layer is the scan with indicators. I take the tickers that triggered a buy alert and run them through a bank comparison of two different banks. An older one and newer one. I only export the tickers that have moved up since the last scan . (3 Weeks in this case) After I have that list (of 3370 tickers in this case) I do an some scans (HT PhasOR here). So now i will only start analyzing the ones that have a buy score of 75 (HTPhasOR) or better. Follow me on X for more. I post more groups of tickers on there to minimize cross-posting.
1 · Reply
mhaven2020
mhaven2020 May. 14 at 8:39 PM
$ELDN l2 AH.
1 · Reply
red1
red1 May. 14 at 7:33 PM
$ELDN a push towards $4 at close will be super bullish
0 · Reply
mhaven2020
mhaven2020 May. 14 at 6:37 PM
$ELDN starting the last scan for the dataset. Should take about 2 hours. I'll have one to enter tomorrow. Stay tuned.
0 · Reply
Littlenicky5280
Littlenicky5280 May. 14 at 6:20 PM
$ELDN got my wife enrolled for phase 3 yesterday. I hope she gets selected. Just bought in a couple days ago too.
1 · Reply
mhaven2020
mhaven2020 May. 14 at 6:17 PM
$ELDN alright here we go!
0 · Reply